Previous close | 130.85 |
Open | 130.85 |
Bid | 131.34 x 1200 |
Ask | 131.27 x 1000 |
Day's range | 126.53 - 132.32 |
52-week range | 119.01 - 497.49 |
Volume | |
Avg. volume | 6,887,137 |
Market cap | 52.234B |
Beta (5Y monthly) | 1.70 |
PE ratio (TTM) | 3.86 |
EPS (TTM) | 34.02 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 220.00 |
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) both delivered major returns for investors in the early days of the coronavirus vaccine race. Moderna's vaccine entered the market in December of 2020. Novavax's vaccine began winning authorizations a year later -- but isn't yet approved in the United States.
Successful money managers used the Nasdaq bear market as a catalyst to buy into these high-growth stocks.
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.